A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)Motoki Yoshida, Akihito Tsuji, Yasuhiro Miyake et al.|Oncology|2016Cited by 14